| Daneisha Arroyo, | |
|
Hc 2 Box 6110, Penuelas, PR 00624-9841 | |
| (787) 696-6474 | |
| Not Available |
| Full Name | Daneisha Arroyo |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | Hc 2 Box 6110, Penuelas, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184046880 | NPI | - | NPPES |
| DAR013089 | Medicaid | PR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 70020GM (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Daneisha Arroyo, Hc 02 Box 6110, Penuelas, PR 00624-9745 Ph: (787) 696-9474 | Daneisha Arroyo, Hc 2 Box 6110, Penuelas, PR 00624-9841 Ph: (787) 696-6474 |
News Archive
Further helping to secure public health, a second round of revised quality standards for the widely used blood thinner heparin became effective today, the U.S. Pharmacopeial (USP) Convention announced. Working closely with the Food and Drug Administration (FDA), the pharmaceutical industry, and other regulatory and scientific bodies, USP started initial revisions in 2008 after adverse reactions and deaths resulted from heparin intentionally adulterated with over-sulfated chondroitin sulfate (OSCS).
HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers.
Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.
Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.
Researchers at the Stanford University School of Medicine have taken an early step toward identifying a new approach to drug discovery that may eventually yield drugs with fewer side effects.
› Verified 1 days ago
Tanairy Olivencia Gonzalez, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Urb Santo Domingo 2, Parcela 157, Penuelas, PR 00624 Phone: 787-462-4804 | |
Aixa Echevarria, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Hc 3 Box 14751, Penuelas, PR 00624 Phone: 787-836-1217 | |
Alanis Nicole Rodriguez Arroyo, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Bo. Santo Domingo 2 Sector Loyola, Penuelas, PR 00624 Phone: 939-592-7267 | |
Ms. Norma Ivette Jordan, BNS Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Hc 1 Box 8393, Penuelas, PR 00624 Phone: 787-836-3636 | |
Denise Feliciano, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Alturas De Penuelas 1, Calle 8 Casa C-7, Penuelas, PR 00624 Phone: 787-617-8142 | |
Ingrid Perez, BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 74, Rpto. Kennedy, Penuelas, PR 00624 Phone: 787-423-0242 |